Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Share-based Compensation (2019 - 2026)

Kymera Therapeutics (KYMR) has disclosed Share-based Compensation for 8 consecutive years, with $16.0 million as the latest value for Q1 2026.

  • For Q1 2026, Share-based Compensation rose 12.46% year-over-year to $16.0 million; the TTM value through Mar 2026 reached $61.7 million, up 7.68%, while the annual FY2025 figure was $59.9 million, 8.89% up from the prior year.
  • Share-based Compensation hit $16.0 million in Q1 2026 for Kymera Therapeutics, up from $14.5 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $16.0 million in Q1 2026 and bottomed at $7.9 million in Q1 2022.
  • Average Share-based Compensation over 5 years is $12.3 million, with a median of $12.0 million recorded in 2024.
  • Year-over-year, Share-based Compensation surged 155.7% in 2022 and then increased 4.74% in 2025.
  • Kymera Therapeutics' Share-based Compensation stood at $8.9 million in 2022, then increased by 22.33% to $10.9 million in 2023, then increased by 26.62% to $13.8 million in 2024, then rose by 4.74% to $14.5 million in 2025, then grew by 10.75% to $16.0 million in 2026.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $16.0 million, $14.5 million, and $15.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.